Capillary leak syndrome natural history, complications and prognosis
Capillary leak syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Capillary leak syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Capillary leak syndrome natural history, complications and prognosis |
FDA on Capillary leak syndrome natural history, complications and prognosis |
CDC on Capillary leak syndrome natural history, complications and prognosis |
Capillary leak syndrome natural history, complications and prognosis in the news |
Blogs on Capillary leak syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
Natural History
The episode usually consists of two phases
The Capillary Leak Phase (1-4 days)
The initial phase is the capillary leak phase, lasting from 1 to 4 days. Clinical features are abdominal pain, nausea, generalized edema and hypotension that may result in cardiopulmonary collapse. Acute renal failure is due to acute tubular necrosis consequent to hypovolemia and rhabdomyolysis.
Recruitment of the Interstitial Fluid
The second phase results in the recruitment of the initially extravasated fluid. Intravascular overload with polyuria and pulmonary edema often occur. Edema may be more severe due to massive fluid supply in the initial phase. It's necessary to monitor the patient in order to switch to depletion treatment with diuretics or hemofiltration.
Prodrome: Weakness, malaise, myalgias, abdominal pain' | |||||||||||||||||||||||||||||||||||||||||||
What is the severity of MR? | |||||||||||||||||||||||||||||||||||||||||||
Severe MR ❑ Severe MVP with loss of coaptation | Progressive MR (Stage B) ❑ Severe MVP with normal coaptation | ||||||||||||||||||||||||||||||||||||||||||
Is the patient symptomatic? | |||||||||||||||||||||||||||||||||||||||||||
Yes (Stage D) | No (Stage C) | ||||||||||||||||||||||||||||||||||||||||||
Is the LVEF>30%? | LVEF 30-60% OR LVESD≥40 mm (Stage C2) | LVEF>60% AND LVESD<40 mm (Stage C1) | New onset atrial fibrillation OR PASP>50 mmHg (Stage C1) | ||||||||||||||||||||||||||||||||||||||||
Is the likelihood of success for the valve repair >95% and the expected mortality <1%? | |||||||||||||||||||||||||||||||||||||||||||
No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||
Mitral valve surgery (Class IIb) | Mitral valve surgery (Class I) | Mitral valve repair (Class IIa) | Periodic monitoring | Periodic monitoring | |||||||||||||||||||||||||||||||||||||||
dications for Surgery in Chronic Secondary Mitral Regurgitation
Shown below is an algorithm depicting the indications for mitral valve surgery or period monitoring among patients with chronic secondary MR according to the 2014 AHA/ACC guideline for the management of patients with valvular heart disease.[1] Note that when mitral valve surgery is indicated, mitral valve repair is preferred over mitral valve replacement whenever feasible.[1]
Abbreviations: MR: mitral regurgitation
Secondary MR and patient is receiving medical therapy | |||||||||||||||||||||||||
What is the severity of MR? | |||||||||||||||||||||||||
Symptomatic (NYHA class III-IV) severe MR (Stage D) | Asymptomatic severe MR (Stage C) | Progressive MR (Stage B) | |||||||||||||||||||||||
Mitral valve surgery (Class IIb) | Periodic monitoring | Periodic monitoring | |||||||||||||||||||||||
Complications
Most common complications of capillary leak syndrome include the following:[2][3]
Complications of Capillary Leak Syndrome |
---|
|
Prognosis
Mortality is reported in 21% of the 57 cases described. However, better management of this condition has recently led to lower mortality.
In the Mayo Clinic’s experience, the median survival of 25 patients that were followed over 30 years (counting only SCLS-related deaths) was approximately 15 years, and their 5-year survival rate was 76%. In European experience, the 5-year post-diagnosis survival rate was 85% in 23 patients who had received prophylactic treatment and 20% in 5 patients who had not. However, better identification and management of this condition appears to be resulting in lower mortality and improving survival and quality-of-life results as of late.
References
- ↑ 1.0 1.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): 2438–88. doi:10.1016/j.jacc.2014.02.537. PMID 24603192.
- ↑ Hajare KR, Patil P, Bansode J (2018). "Idiopathic Systemic Capillary Leak Syndrome". Indian J Crit Care Med. 22 (5): 369–371. doi:10.4103/ijccm.IJCCM_464_17. PMC 5971649. PMID 29910550.
- ↑ Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC; et al. (2010). "Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience". Mayo Clin Proc. 85 (10): 905–12. doi:10.4065/mcp.2010.0159. PMC 2947962. PMID 20634497.